Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications. The company also offers Troriluzole for spinocerebellar ataxia and obsessive compulsive disorders, as well as Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000/5500 for neuropsychiatric indications; and Verdiperstat, a product for multiple system atrophy and amyotrophic lateral sclerosis. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was incorporated in 2013 and is headquartered in New Haven, Connecticut.
P/E ratio for Biohaven Pharmaceutical Holding Company Ltd. (BHVN)
P/E ratio as of 2023: -7.47
According to Biohaven Pharmaceutical Holding Company Ltd.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -7.47. At the end of 2022 the company had a P/E ratio of -1.09.
P/E ratio history for Biohaven Pharmaceutical Holding Company Ltd. from 2017 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -7.47 |
| 2022 | -1.09 |
| 2021 | -1.22 |
| 2020 | -2.20 |
| 2019 | -0.67 |
| 2018 | 0.00 |
| 2017 | 0.00 |